SecProbe.io

<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>

						June 28, 2005

Via Facsimile ((212) 687-3521) and U.S. Mail

James M. Rae, Esq.
Stairs Dillenbeck Finley
330 Madison Avenue
29th Floor
New York, NY  10017

Re:	Meditech Pharmaceuticals, Inc.
	Schedule 14F-1 filed June 15, 2005
	SEC File No. 005-36623

Dear Mr. Rae:

      We have reviewed your filing and have the following
comments.
Where indicated, we think you should revise your document in
response
to these comments.  If you disagree, we will consider your
explanation as to why our comment is inapplicable or a revision is
unnecessary.  Please be as detailed as necessary in your
explanation.
In some of our comments, we may ask you to provide us with
information so we may better understand your disclosure.  After
reviewing this information, we may raise additional comments.

	Please understand that the purpose of our review process is
to
assist you in your compliance with the applicable disclosure
requirements and to enhance the overall disclosure in your filing.
We look forward to working with you in these respects.  We welcome
any questions you may have about our comments or any other aspect
of
our review.  Feel free to call us at the telephone numbers listed
at
the end of this letter.

Schedule 14F-1

Security Ownership of Certain Beneficial Owners, page 2
1. We note the footnote disclosure that the four security holders
listed in this section filed a joint Schedule 13D.  Please tell us
why that schedule was filed jointly, as none of the filing persons
shares in the voting or dispositive authority over the shares of
any
other filing person, per the Schedule 13D.  If the filing persons
agreed to act together in the manner described in Rule 13d-5(b),
please revise the table in this section to include in each
person`s
line-item the shares held of record by the other persons, which
would
appear to be beneficially owned by all four persons.
2. Please reconcile the aggregate percentage of shares held by the
persons listed in this table from the introductory paragraph
(65.2%)
to the table itself (64.2%).
3. Please reconcile the number of shares held by Mr. Du in this
table
(18,879,747 shares) and in the table on page 3 (18,542,191
shares).

Directors, Executives, Nominee Directors, page 3
4. Please provide the disclosure required by instruction 4 to Item
103 of Regulation S-B.  If the required disclosure is not
applicable
due to the absence of any proceedings of the type described in the
regulation, please state so.
5. Provide the disclosure required by Item 404(a) of Regulation S-
B.
Note that this requirement applies to the registrant in its
current
organization, including the operations of Deli Solar Holding and
its
subsidiaries.

Corporate Governance, page 5
6. Given that you do not have a nominating committee, please
provide
the information required by Item 7(d)(2)(i) of Schedule 14A.
7. Please provide the information required by Item 7(f) of
Schedule
14A.

Executive Compensation, page 5
8. Provide confirm that you have provided complete disclosure in
response to Item 402(a) of Regulation S-B.  Note that this
requirement applies to the registrant in its current organization,
including the operations of Deli Solar Holding and its
subsidiaries.

Closing Comments

      As appropriate, please amend your filing and respond to
these
comments within 10 business days or tell us when you will provide
us
with a response.  You may wish to provide us with marked copies of
the amendment to expedite our review.  Please furnish a cover
letter
with your amendment that keys your responses to our comments and
provides any requested information.  Detailed cover letters
greatly
facilitate our review.  Please understand that we may have
additional
comments after reviewing your amendment and responses to our
comments.

	We urge all persons who are responsible for the accuracy and
adequacy of the disclosure in the filing to be certain that the
filing includes all information required under the Securities
Exchange Act of 1934 and that they have provided all information
investors require for an informed investment decision.  Since the
company and its management are in possession of all facts relating
to
a company`s disclosure, they are responsible for the accuracy and
adequacy of the disclosures they have made.

	In connection with responding to our comments, please
provide,
in writing, a statement from the company acknowledging that:

* the company is responsible for the adequacy and accuracy of the
disclosure in the filing;

* staff comments or changes to disclosure in response to staff
comments do not foreclose the Commission from taking any action
with
respect to the filing; and

* the company may not assert staff comments as a defense in any
proceeding initiated by the Commission or any person under the
federal securities laws of the United States.

      In addition, please be advised that the Division of
Enforcement
has access to all information you provide to the staff of the
Division of Corporation Finance in our review of your filing or in
response to our comments on your filing.

      Please direct any questions to me at (202) 551-3619 or, in
my
absence, to Christina Chalk, Special Counsel, at (202) 551-3263.
You
may also contact me via facsimile at (202) 772-9203.  Please send
all
correspondence to us at the following ZIP code: 20549-0303.

						Sincerely,

						Daniel F. Duchovny
						Attorney-Advisor
						Office of Mergers and Acquisitions

??

??

??

??

James M. Rae, Esq.
Stairs Dillenbeck Finley
June 28, 2005
Page 1

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

         DIVISION OF
CORPORATION FINANCE

</TEXT>
</DOCUMENT>